Type: Keyphrase
Name: L-Dopa
First reported 1 hour ago - Updated 1 hour ago - 1 reports

Parkinson's Drugs Linked to Sex and Gambling Addictions

Pathological gambling, hypersexuality and compulsive shopping are some of the abnormal behaviors that are linked to the use of certain drugs commonly used to treat Parkinson's disease, according to a new study.The findings are important because they mean ... [Published Yahoo! News - 1 hour ago]
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

Killer in the brain could help treat Parkinson's

(Image: Soledad Galli, Parkinson's UK / University College London)This glowing blue web of neurons is usually what researchers examine when searching for a cure for Parkinson's. But a new study that hones in on the tiny yellow dots, connections between ... [Published New Scientist - Oct 17 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

Levodopa dose linked to malnutrition risk in Parkinson’s disease

medwireNews: The malnutrition often seen in patients with Parkinson’s disease (PD) could be partly an effect of levodopa medication, research suggests.Alice Laudisio (Campus Bio-Medico University, Rome, Italy) and colleagues found that the presence of ... [Published MedWire News - Oct 17 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

Titan Pharmaceuticals : Patent Issued for Implantable Polymeric Device for Sustained Release of Dopamine Agonist

By a News Reporter-Staff News Editor at Biotech Week -- Titan Pharmaceuticals, Inc. ( South San Francisco, CA ) has been issued patent number 8852623, according to news reporting originating out of Alexandria, Virginia , by NewsRx editors (see also Biotechnology ... [Published 4 Traders - Oct 16 2014]
First reported Oct 15 2014 - Updated Oct 15 2014 - 1 reports

New therapies to treat niche populations will drive Parkinson’s market

The Parkinson’s disease (PD) pharmacotherapy market will grow 5% annually from $2.3 billion in 2013 to $3.8 billion in 2023, new research finds.This growth will be fueled by the launch of several emerging therapies - including new molecular entities in ... [Published Pharma Letter - Oct 15 2014]
First reported Oct 13 2014 - Updated Oct 13 2014 - 1 reports

Parkinson's Disease

Parkinson’s disease (PD) is a progressive neurological disorder. It first presents with problems of movement.Smooth and coordinated muscle movements of the body are made possible by a substance in the brain called dopamine. Dopamine is produced in ... [Published Auto.ru.msn.com - Oct 13 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

NeuroDerm's Proposed IPO Represents A New Parkinson's Play

Summary NeuroDerm's innovative therapies could disrupt current pipelines and practice. Analysis of the Parkinson's problem of "off" episodes. Potential impact on "rescue" therapies currently being developed - ACOR and CYNAF.On September 15, 2014, NeuroDerm ... [Published Seeking Alpha - Oct 07 2014]
Entities: L-Dopa, Dyskinesia, Dopamine, IPO
First reported Sep 29 2014 - Updated Sep 30 2014 - 2 reports

Amarantus requests pre-IND feedback from FDA

Amarantus Bioscience Holdings (OTCQB:AMBS) has submitted a request to the FDA for a review and written feedback of the Phase 2b clinical trial design for Eltoprazine in levodopa-induced dyskinesia (LID), a common side effect of levodopa treatment in Parkinson’s ... [Published BioPortfolio - Sep 30 2014]
First reported Sep 28 2014 - Updated Sep 28 2014 - 1 reports

Levodopa . Order Levodopa No Prescription Required, Discount Online Levodopa Cod

levodopa . Order levodopa no prescription required, discount online levodopa codMed Portal has proved its reliability and safety, working at pharmaceutical market since 2003. One of the most urgent problems in online pharmacy business is the quality of ... [Published Student Village - Sep 28 2014]
Entities: L-Dopa, Cheap, Discount
First reported Sep 26 2014 - Updated Sep 27 2014 - 3 reports

Acorda Therapeutics to acquire Civitas Therapeutics

Acorda Therapeutics , a biotechnology company based in Ardsley, N.Y., has entered into an agreement to acquire Civitas Therapeutics , a Chelsea, Mass.-based, privately held biopharmaceutical company, for $525 million in cash. Acorda will obtain worldwide ... [Published Center Watch - Sep 27 2014]
First reported Sep 24 2014 - Updated Sep 25 2014 - 14 reports

Alkermes manufacturing technology key to Acorda buyout of Civitas

Alkermes developed the inhaler technology and built the plant where Civitas makes the drugShareToolsYet another biotech M&A deal was announced this week, this time with Ardsley, NY-based Acorda Therapeutics agreeing to buy Civitas Therapeutics for $525 ... [Published FiercePharmaManufacturing - Sep 25 2014]
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports


AbstractPatel T, Chang F. Parkinson’s disease guidelines for pharmacists. Can Pharm J (Ott) 2014;147:161-170. (Original DOI: 10.1177/1715163514529740 ).Several clarifications have been made to Table 2 of the above article. The updated information below ... [Published Canadian Pharmacists Journal - Sep 23 2014]


"In summary, physicians have overestimated the benefit and underestimated the risks associated with the use of dopamine receptor agonist drugs in patients with Parkinson disease" they wrote
...for biotechnology product development and commercial oversight in the United States," said Gerald E Commissiong, President & CEO of Amarantus. "I'm very happy to become formally involved in this important effort. BIO is the world's largest trade organization representing biotech organizations across the United States and in more than 30 other nations. Its initiatives include improving products, from development to commercialization, which are invaluable to patients in the safest and most efficacious manner possible."
...College London and her colleagues have found that the death of synapses in mice may be duedue to malfunctioning proteins called Wnt proteins. "If we confirm that Wnt is involved in the early stages of Parkinson's, this throws up exciting possibilities, not just for new treatment targets, but also for new ways to identify people with Parkinson's early on in their condition" says Galli
"We have enjoyed 12 exits in the past 12 months and so when your relationships with your LPs (limited partners) are quite positive - and we've had LPs who have supported us over many years - the fundraising went quite smooth for us" Hutton said

More Content

All (143) | News (116) | Reports (0) | Blogs (24) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Parkinson's Drugs Linked to Sex and Gambling Ad... [Published Yahoo! News - 1 hour ago]
Addictive Personality Traits May Result From Do... [Published Medical Daily - 1 hour ago]
Amarantus CEO Gerald Commissiong Elected to Bio... [Published Good Day Sacramento - 10 hours ago]
Levodopa dose linked to malnutrition risk in Pa... [Published MedWire News - Oct 17 2014]
Killer in the brain could help treat Parkinson's [Published New Scientist - Oct 17 2014]
Pioneers in Neurostimulation: Lasker Awardees A... [Published Neurology Today - Oct 17 2014]
California VC Firm Raises $675M; More Than $200... [Published Medical Device & Diagnostic Industry - Oct 16 2014]
Canaan debuts $675M fund with an eye for biotec... [Published FierceBiotech - Oct 16 2014]
Researchers define the process of Parkinson's d... [Published News-Medical.Net - Oct 16 2014]
Sublingual films [Published PharmCast - Oct 16 2014]
Titan Pharmaceuticals : Patent Issued for Impla... [Published 4 Traders - Oct 16 2014]
New therapies to treat niche populations will d... [Published Pharma Letter - Oct 15 2014]
Stop ‘Stoptober’: seven health benefits associa... [Published The Coffee House | Politics and News Discussion ... - Oct 15 2014]
Taking a shot at Parkinson’s [Published University of Cambridge - Oct 15 2014]
How toxic proteins stress nerve cells: Biomarke... [Published Medical Xpress - Oct 14 2014]
Parkinson: How toxic proteins stress nerve cells [Published EurekAlert! - Oct 14 2014]
Parkinson's Disease [Published Auto.ru.msn.com - Oct 13 2014]
ProSolution Plus Review: A Natural Remedy For P... [Published Examiner.com - Oct 11 2014]
Alkame Holding’s Share Value Continues to fall ... [Published Accesswire - Oct 09 2014]
Amarantus Announces Positive LP-002 Data for Al... [Published Industrial Info Financials - Oct 09 2014]
Researchers Submit Patent Application, "Use of ... [Published 4 Traders - Oct 08 2014]
NeuroDerm's Proposed IPO Represents A New Parki... [Published Seeking Alpha - Oct 07 2014]
Amarantus Investigator Presents Positive MANF A... [Published CW 50 Detroit - Oct 07 2014]
Gift Will Aid Research Into Rare Brain Disorder [Published University of Cincinnati - Oct 06 2014]
MEDTRONIC : Patent Application Titled "Injectab... [Published 4 Traders - Oct 04 2014]
Adamas Pharmaceuticals’ Lock-Up Period Will Exp... [Published American Banking News - Forex - Oct 02 2014]
Biogen Idec's Strategy For Neurology R&D Success [Published Life Science Leader - Oct 02 2014]
International Stem Cell Update on Disease Program [Published MoneyAM - Oct 02 2014]
At Birthday Symposium, Massachusetts ADRC Looks... [Published Alzheimer Research Forum - Oct 01 2014]
Natural anti aging supplements to slow down the... [Published FreePressIndex.com - Oct 01 2014]
1 2 3 4 5
In Focus
Content Volume
Document Volume


sort by: Date | Relevance
Mapheads and Roadgeeks: The New Cartography [Published IEEE Spectrum - Sep 29 2014]
<?xml version="1.0" encoding="UTF-8"?>.pullquote {font-style: normal;border-top-width: 2px;border-top-color: #aaaaaa !important;border-top-style: solid;padding-top: 10px;border-bottom-width: 2px;border-bottom-style: solid;border-bottom-color: #aaaaaa ...
[Department of Error] Department of Error [Published The Lancet - Sep 26 2014]
PD MED Collaborative Group. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 2014; 384: ...
NeuroDerm Announces Start of Phase 2a Study of ... [Published PR Newswire: Policy & Public Interest - Sep 03 2014]
REHOVOT, Israel, September 3, 2014 /PRNewswire/ --NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that the first patients with severe Parkinson's disease have been enrolled ...
Civitas Therapeutics scores $55 mln Series C [Published PE Hub Blog - Aug 26 2014]
Civitas Therapeutics has closed $55 million in Series C funding. The investors included Adage Capital Management, OrbiMed Advisors, Partner Fund Management, Rock Springs Capital, Sofinnova Ventures, Alkermes plc, Bay City Capital, Canaan Partners, ...
NeuroDerm Announces Eligibility for European Un... [Published PR Newswire: Policy & Public Interest - Aug 04 2014]
REHOVOT, Israel, August 4, 2014 /PRNewswire/ --NeuroDerm Ltd. today announced that the European Medicines Agency (EMA) has deemed ND0612H, its product candidate offering continuous delivery of levodopa/carbidopa (LD/CD) treatment for advanced Parkinson's ...
1 2 3 4 5

Press Releases

sort by: Date | Relevance
Amarantus Requests Pre-IND Feedback From FDA fo... [Published GlobeNewswire: Acquisitions News - Sep 29 2014]
Biotie: Tozadenant Phase 2b Parkinson's disease... [Published GlobeNewswire: Advertising News - Jul 08 2014]
Contact Us

Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.